Gene discovery limits tumor risk for stem cell therapy

Hebrew University researchers analyzed the genetic basis of tumor formation and identified a key gene involved in this unique tumorigenicity.

By
May 30, 2009 22:37
1 minute read.
fetus 88

fetus 88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

A method to potentially eliminate the tumor-risk factor when using human embryonic stem cells (hESCs) - developed by researchers at the Hebrew University of Jerusalem - has paved the way for further progress in stem cell therapy. These stem cells, taken from human embryos not used for in-vitro fertilization, are theoretically capable of differentiation into all types of cells, and are thus defined as "pluripotent." This ability, along with remaining undifferentiated indefinitely in culture, make regenerative medicine using hESCs a potentially unprecedented tool for the treatment of various diseases, including diabetes, Parkinson's disease and heart failure. A major drawback to the use of stem cells, however, remains the demonstrated tendency of such cells to grow into a specific kind of tumor called teratoma when they are implanted in laboratory mice. It is assumed that this tumorigenic feature will occur when they are transplanted into humans as well. The development of tumors from embryonic stem cells is especially puzzling, given that these cells start out completely normal. A team of researchers at the stem cell unit in the Hebrew University's Silberman Institute of Life Sciences genetics department have been working on various approaches to deal with this problem. The researchers are headed by Prof. Nissim Benvenisty and doctoral student Barak Blum. In their latest project, the researchers analyzed the genetic basis of tumor formation from hESCs and identified a key gene involved in this unique tumorigenicity. This gene, called survivin, is expressed in most cancers and in early-stage embryos, but is almost completely absent from mature tissues. The survivin gene is very highly expressed in undifferentiated hESCs and in their derived tumors. By neutralizing the activity of survivin in the undifferentiated cells and the tumors, the researchers were able to initiate programmed cell death (apoptosis) in those cells. The inhibition of this gene just before or after transplantation of the cells could minimize the chances of tumor formation, but the researchers caution that a combination of strategies may be needed to address the safety concerns regarding tumor formation by human embryonic stem cells. A report on this latest HU project appeared in the online edition of Nature Biotechnology. Others working on the project are Ph.D. student Ori Bar-Nur and laboratory technician Tamar Golan-Lev.

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia

By UNIVERSITY OF MICHIGAN HEALTH SYSTEM